Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding a press release dated April 27, 2026, titled "Press Release for Audited Financial Results for quarter and year ended March 31, 2026".
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.3 pts more than Nifty Microcap 250 and 2.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jagsonpal Pharmaceuticals reported Q4FY26 revenue of ₹642 Mn, up 9.6% YoY, with PAT rising 31% to ₹88 Mn. Full-year FY26 revenue grew 6.9% to ₹2,872 Mn while operational PAT climbed 19% to ₹446 Mn. EBITDA margins were largely flat, slipping modestly to 21.2% (FY26) and 16.4% (Q4) on a pre-ESOP basis. The company announced a ₹40 Cr buyback at ₹250 per share (16 lakh shares, 2.4% of equity, promoters not participating) and a 200% dividend (including 75% special dividend). Cash position stood strong at ₹191 Cr. The company outpaced the Indian pharmaceutical market, growing 12.2% vs IPM's 8.6%.
Positive for shareholders — the buyback at a ~40% premium to market and higher dividend signal strong capital return, while the 19% PAT growth and market outperformance reinforce confidence. Margin guidance of 100-150 bps improvement for FY27 should support earnings momentum.